Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification

Virologica Sinica

Volumn 25, Issue 5, 2010, Pages 316-328

  Geng, Qing Mao ^a   Li, Han Ping ^a   Bao, Zuo Yi ^a   Liu, Yong Jian ^a   Zhuang, Dao Min ^a   Li, Lin ^a   Liu, Si Yang ^a   Li, Jing Yun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Indinavir; M46I G73S L90M Mutation Pattern; Resistance Evolution; Single Genome Amplification

Indexed keywords

DIDANOSINE; INDINAVIR; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DATA BASE; FOLLOW UP; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS GENOME; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INDINAVIR; MALE; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78249240607     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-010-3122-4     Document Type: Article

References (26)

1. D. C. Alexander 1990 A rapid method for determining clone frequency in complex populations using PCR and the Poisson distribution Nucl Acids Res 18 24 7453 7454 1:CAS:528:DyaK3MXns1eisQ%3D%3D 10.1093/nar/18.24.7453 2259641
2. + T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy J Infect Dis 181 5 1808 1812 10.1086/315429 10823790 (Pubitemid 30387783)
3. Z. Chen Y. Li H. B. Schock, et al. 1995 Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials J Biol Chem 270 37 21433 21436 1:CAS:528:DyaK2MXotFajtLg%3D 10.1074/jbc.270.37.21942 7665551
4. F. Clavel A. J. Hance 2004 HIV drug resistance N Engl J Med 350 10 1023 1035 1:CAS:528:DC%2BD2cXhvFGjs7c%3D 14999114
5. J. M. Coffin 1995 HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 267 483 489 1:CAS:528:DyaK2MXjsFShu7w%3D 10.1126/science.7824947 7824947
6. J. H. Condra D. J. Holder W. A. Schleif, et al. 1996 Genetic correlates of in vivo viral resistance to Indinavir, a Human Immunodeficiency Virus type 1 protease inhibitor J Virol 70 12 8270 8276 1:CAS:528:DyaK28XmvVGnurc%3D 8970946
7. D. Descamps V. Joly P. Flandre, et al. 2005 Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073) J Clin Virol 33 99 103 1:CAS:528:DC%2BD2MXks1aqsbs%3D 10.1016/j.jcv.2004.05.019 15911424 (Pubitemid 40725302)
8. M. Dybul M. Daucher M. A. Jensen, et al. 2003 Genetic characterization of rebounding Human Immunodeficiency Virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy J Virol 77 5 3229 3237 1:CAS:528:DC%2BD3sXhsVOhu7g%3D 10.1128/JVI.77.5.3229-3237.2003 12584346 (Pubitemid 36228106)
9. H. F. Gunthard J. K. Wong C. C. Ignacio, et al. 1998 Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples AIDS Res Hum Retroviruses 14 869 876 1:CAS:528:DyaK1cXksV2qtbk%3D 10.1089/aid.1998.14.869 9671215
10. A. H. Kaplan S. F. Michael R. S. Wehbie, et al. 1994 Selection of multiple Human Immunodeficiency Virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease Proc. Natd. Acad. Sci 91 5597 5601 1:CAS:528:DyaK2cXlsVygu7s%3D 10.1073/pnas.91.12. 5597 (Pubitemid 24174375)
11. E. Kinai H. Hanabusa S. Kato 2007 Prediction of the efficacy of antiviral therapy for Hepatitis C Virus infection by an ultrasensitive RT-PCR assay J Med Virol 79 1113 1119 1:CAS:528:DC%2BD2sXotl2ktb0%3D 10.1002/jmv.20908 17596840 (Pubitemid 47015410)
12. M. Kondo K. Sudo R. Tanaka, et al. 2009 Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR J Virol Methods 157 141 146 1:CAS:528:DC%2BD1MXktF2qsLg%3D 10.1016/j.jviromet.2008.12.006 19126416
13. L. M. Mansky H. M. Temin 1995 Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase J Virol 69 5087 5094 1:CAS:528:DyaK2MXmvFWgtr0%3D 7541846
14. S. Palmer M. Kearney F. Maldarelli, et al. 2005 Multiple, linked Human Immunodeficiency Virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis J Clin Microbiol 43 1 406 413 1:CAS:528:DC%2BD2MXhtF2msr8%3D 10.1128/JCM.43.1.406-413.2005 15635002 (Pubitemid 40096331)
15. A. S. Perelson A. U. Neumann M. Markowitz, et al. 1996 HIV-1 dynamics in vivo: viron clearance rate, infected cell life-span, and viral generation time Science 271 5255 1582 1586 1:CAS:528:DyaK28XhslSjsbY%3D 10.1126/science.271. 5255.1582 8599114
16. B. D. Preston B. J. Poiesz L. A. Loeb 1988 Fidelity of HIV-1 reverse transcriptase Science 242 1168 1171 1:CAS:528:DyaL1MXhs12jtrw%3D 10.1126/science.2460924 2460924
17. S. Y. Rhee J. Taylor G. Wadhera, et al. 2006 Genotypic predictors of human immunodeficiency virus type 1 drug resistance Proc Natl Acad Sci USA 103 17355 17360 1:CAS:528:DC%2BD28Xht1KqsbrL 10.1073/pnas.0607274103 17065321 (Pubitemid 44788973)
18. T. W. Ridky A. Kikonyogo J. Leis, et al. 1998 Drugresistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate Biochemistry 37 39 11835 11845 10.1021/bi980612k (Pubitemid 28455561)
19. J. D. Roberts K. Bebenek T. A. Kunkel 1988 The accuracy of reverse transcriptase from HIV-1 Science 242 1171 1173 1:CAS:528:DyaL1MXjs1SmsQ%3D%3D 10.1126/science.2460925 2460925
20. C. M. Rousseau B. A. Birditt A. R. McKay, et al. 2006 Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes J Virol Methods 136 118 125 1:CAS:528:DC%2BD28XntVylsL8%3D 10.1016/j.jviromet.2006.04.009 16701907 (Pubitemid 44081956)
21. A. J. Saah D. W. Haas DiNubile, et al. 2003 Treatment with Indinavir, Efavirenz, and Adefovir after failure of Nelfinavir therapy J Infect Dis 187 7 1157 1162 1:CAS:528:DC%2BD3sXjtlekurs%3D 10.1086/368287 12660932 (Pubitemid 36399359)
22. J. F. Salazar-Gonzalez E. Bailes K. T. Pham, et al. 2008 Deciphering Human Immunodeficiency Virus type 1 transmission and early envelope diversification by single genome amplification and sequencing J Virol 82 8 3952 3970 1:CAS:528:DC%2BD1cXksFWrur0%3D 10.1128/JVI.02660-07 18256145 (Pubitemid 351521232)
23. R. Schuurman D. Brambilla T. D. Groot, et al. 2002 Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program AIDS Res Hum Retroviruses 18 243 248 1:CAS:528: DC%2BD38Xit1WrurY%3D 10.1089/088922202753472801 11860670 (Pubitemid 34253141)
24. P. Simmonds P. Balfe J. F. Peutherer, et al. 1990 Human Immunodeficiency Virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers J Virol 64 2 864 872 1:STN:280:DyaK3c7ht1Kmug%3D%3D 2296085
25. P. J. Sykes S. H. Neoh M. J. Brisco, et al. 1992 Quantitation of targets for PCR by use of limiting dilution Biotechniques 13 3 444 449 1:CAS:528:DyaK3sXhslSksw%3D%3D 1389177
26. S. H. Yap C. W. Sheen J. Fahey, et al. 2007 N348I in the connection domain of HIV-1 reverse transcriptase confers Zidovudine and Nevirapine resistance Plos Med 4 12 1887 1899 1:CAS:528:DC%2BD1cXmvVSlsLk%3D 10.1371/journal.pmed.0040335